Pharmaceutical Executive
Though uncertain market dynamics remain at play, the current magnitude of innovation in biopharma is staggering, and, at times, overwhelming.
I’ve touched on this point a few times over the years, there is no such thing as an overnight success. What looks like an overnight success is really a good chunk of years of someone’s life, laboring at a point of science-in this world of therapy development-of which they couldn’t let go. And many of these innovations, while they
Lisa Henderson
have a few successes, CAR-T, gene therapy, immunotherapy, are still in their infancy. Scientists may have been laboring at their research for 20, 25, 30 years, but the current magnitude of innovation is staggering, and, at times, overwhelming.
Salim Syed, head of biotechnology research, senior biotechnology analyst and managing director at Mizuho, says, “There is so much innovation going on. Biotech is going faster and faster and no longer can any one person know everything about all that is out there.” And it is clear that this innovation invasion is not lost on pharma executives themselves. Here’s a sampling of what some recent executives have said about innovation and partnering with biotech.
All of these points are not lost on Syed, who in his various roles at Mizuho, deals with the financial questions of biotech every day. To Jiminez’s point, pharma is now looking to get into technologies very early, before they are in clinical stage.
“Five years ago, you would never look at companies that were pre-Phase II; if they wanted to go public, they needed data. Now, they have no data, or are preclinical, or have very small and early 10-20 patient trials,” says
Syed.
“Will that reverse trend in 2020?” he posed. As with most industries, a watchful eye is on the 2020 election year-and where these biotechs want to be is now a concerning business question.
There are certain things that can stall the pace of innovation. Past examples include an early death in gene therapy that set a chilling effect on that area in the late 1990s; transplantation advances that were shut down during the AIDS crisis; and Vioxx taken off the market in the early 2000s for CV events. Each one of these areas are now new and vital parts of therapeutic innovation, but they had to weather a storm, and in the end, the science grew stronger.
Financial pressures from uncertain market dynamics, including elections and overall drug pricing and reimbursement concerns, all have effects. But how chilling will they be? With the pace of massive innovation, it seems nothing can stem the tide.
Lisa Henderson is Editor-in-Chief of Pharm Exec. She can be reached at lhenderson@mmhgroup.com. Follow Lisa on Twitter: @trialsonline
FDA Outlines Updated Requirement for Placebo-Controlled Trials in Vaccine Research
May 21st 2025In an article recently published by The New England Journal of Medicine, FDA higher-ups Vinay Prasad, MD, MPH; and Martin A. Makary, MD, MPH, wrote that any new COVID-19 vaccine must now be evaluated in placebo-controlled studies.
Addressing Disparities in Psoriasis Trials: Takeda's Strategies for Inclusivity in Clinical Research
April 14th 2025LaShell Robinson, Head of Global Feasibility and Trial Equity at Takeda, speaks about the company's strategies to engage patients in underrepresented populations in its phase III psoriasis trials.
Undertreated but High-Risk: The Hidden Health Crisis Facing 50+ Americans
May 15th 2025Leandro Boer, MD, PhD, VP, US general medicines, Amgen, explains why many high-risk Americans aged 50+ remain undertreated for cardiovascular disease, citing insurance gaps, risk misperceptions, and complex guidelines.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.
Novo Nordisk’s Sogroya Demonstrates Efficacy in Children with Growth Disorders
May 14th 2025Results from the Phase III REAL8 basket study found that once-weekly Sogroya was effective in children with growth disorders, including those born small for gestational age, with Noonan syndrome, or idiopathic short stature.